GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences

This research project investigates the lived experiences of children and young people (CYP) who use GLP‑1 receptor agonists—such as semaglutide and liraglutide—for weight management, addressing a critical gap in understanding how these rapidly emerging treatments affect CYP beyond physiological outcomes. Against a backdrop of rising paediatric obesity and expanding use of GLP‑1 medications in clinical settings, the project systematically reviews qualitative studies to explore emotional, psychological, social, and practical aspects of treatment, including feelings about rapid weight change, fears around medication discontinuation, identity development, adherence challenges, and family or contextual influences. By synthesising experiential evidence, the review aims to clarify real‑world challenges such as access inequities and acceptability, while generating insights that can improve clinical practice, inform policy, and guide future research on safe, equitable, and developmentally appropriate obesity care for CYP, and highlight any gaps in knowledge to be further explored.